

TESTIMONIALS — EXECUTIVE EDITORIAL BOARD, INTERNATIONAL EDITORIAL ADVISORY BOARD

I would like to express my sincere gratitude for the invitation to join *GaBI Journal's* International Editorial Advisory Board. I endeavour to do my best to promote, support and raise awareness of the journal to colleagues, contacts and stakeholders especially around the Asia/ASEAN region. The journal is a very worthy effort to encourage understanding and appreciation of generics and biosimilars.

Congratulations on the successful launch of *GaBI Journal*, 2012, Volume 1. It is very good and surely commands wide readership.

Arpah Abas,
Deputy Director/Head of Biotechnology Section
Ministry of Health Malaysia, Malaysia

Congratulations for the start of the *GaBI Journal* which was highly anticipated and now perfectly completes the activities of GaBI's web presence and the weekly newsletter. The journal may become very soon rather important in a field where qualitative information is urgently needed, and in fact that is exactly what the journal offers. Well done and already looking forward to the second issue!

Christoph Baumgärtel, MD
Head of Department, Austria
AGES PharmMed/Austrian Medicines Authority, Austria

TESTIMONIALS — ACADEMICS, PHARMACISTS

The intention of GaBI is to generate a service for healthcare providers to support them in making cost-effective choices when it comes to treatment decisions. I see that as a noble objective.

Congratulations! *GaBI Journal* looks great, it has a wide variety of topics, depth and international spread. I wish to congratulate GaBI team for this achievement! This open access strategy works — we get a huge number of page views for journal articles. The next step is to start citing the journal articles.

Professor Arnold Vulto, PharmD, PhD, The Netherlands

Congrats! Well done! I really have found GaBI extremely informative and helpful. Thank you!

Professor Anthony Sinclair, Pharmacist, UK

TESTIMONIALS — INDUSTRY

Congratulations to the first edition which is very impressive. We keep it in the office for customers and employees to look inside whenever they feel like it. It is a serious voice of the generics business.

Dr Martin Spatz, MBA, General Manager
Ratiopharm Arzneimittel Vertriebs-GmbH, Austria

Thanks for the journals. They were very well appreciated here. The team at GaBI has done a fabulous work on the journal and I would like to commend all of you on the effort. Looking forward to hearing from you again.

Sweta Pachlangiya, Investor Relations, Business Analytics
Biocon Limited, India

I was delighted to receive my hard copy of the first issue of the *GaBI Journal* – congratulations on a highly successful launch. The issue contains much interesting and informative content, and I am looking forward to reading it cover to cover.

The journal is extremely well positioned to be a leader in the field and I am happy to be associated with it as a member of the editorial board.

Janice M Reicher, PhD, Research Assistant Professor
Tufts University School of Medicine, USA

Congratulations on your first issue of the *GaBI Journal*, and thank you for inviting us as contributors to this project.

The journal appears scientifically interesting, appropriately varied and professional, and the design is delicate and appealing.

Helle Håkonsen, MScPharm, PhD
School of Pharmacy, University of Oslo, Norway

Patients need access to quality, cost-effective medicines whether they are brand name or generics.

Professor Philip D Walson, MD, USA

Patients should take drugs in an optimal way and at an affordable and realistic cost.

Dr Rob Janknegt, PharmD, PhD, The Netherlands

Firstly, I would like to congratulate you all for this great initiative. It is indeed very important for us, healthcare providers, to have such a support in making choices that are so important for the population in so many aspects. As a pharmacist, I appreciate reading articles concerning the safety and cost-effectiveness of biosimilars.

Dr Alvaro Moreno, Pharmacist, Latin America

I think GaBI is doing a great job and GaBI is getting a good name. As a co-author of an article, the process has been fine and I want to highlight the thoroughness of the manuscript review.

Professor Jaime Espin, PhD, Spain

The editors and the research team of *GaBI Journal* have done a tremendous job and are way ahead in the game of biosimilars. GaBI website is a *One Stop Shop* that addresses the most pressing issues in the generics and biosimilars domain. In the near future, I can see GaBI as a leader in keeping the industry and, more importantly, the students in the field of biopharmaceuticals, well informed with precise and credible business and science aspects of follow-on medicinal products.

Mr Maulik Panchal, Senior Regulatory Affairs Associate,
Amgen Inc, USA